Thrombosis Clinical Trial
Official title:
A Single Center, Randomised Study to Investigate Pharmacokinetics of CS1, Safety and Tolerability and in Obese, Borderline Hypertensive But Otherwise Healthy and Medicine Free Subjects After Administration of Single and Multiple Doses
SAD study:
Eighteen subjects will be included in the SAD study (single dose) in 3 parallel arms, each
with 6 subjects. The 3 arms will receive a single dose of one of the CS1 formulations I, II
or III. The result of the pharmacokinetics analysis from the 6 first subjects is defined as
SAD Pilot and will be used to evaluate the timing of PK sampling. Based on pharmacokinetic
evaluations from all 18 subjects one of the formulations I (275 mg), II (276 mg) or III (276
mg) will be chosen to proceed into the MAD study. If none of the formulations show the
desired PK properties the formulations may be re-dosed with a slightly different timing of
the dose, i.e the IMP to be administered earlier or later during the evening.
MAD study:
Fifteen subjects will be included in a dose escalating study with 2 dose levels. The subjects
will receive the lowest dose level (275 or 276 mg depending on the outcome of SAD) for the
first 2 weeks before the dose is doubled (550 or 552 mg depending on the outcome of SAD) for
the following 2 weeks.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03826043 -
THrombo-Embolic Event in Onco-hematology
|
N/A | |
| Recruiting |
NCT04398628 -
ATHN Transcends: A Natural History Study of Non-Neoplastic Hematologic Disorders
|
||
| Completed |
NCT05426564 -
Exploratory Assessment of the Quantra® System in Adult ECMO Patients
|
||
| Not yet recruiting |
NCT05830916 -
Diagnostic Role of Antiphospholipid Antibodies and Microparticles in Immune Thrombocytopenic Patients With Thrombosis
|
||
| Recruiting |
NCT02972385 -
Pharmacogenomics of Warfarin in Hispanics and Latinos
|
||
| Completed |
NCT02917213 -
Imaging Silent Brain Infarct And Thrombosis in Acute Myocardial Infarction
|
||
| Completed |
NCT02526628 -
Thrombosis and Neurocognition in Klinefelter Syndrome
|
||
| Completed |
NCT02439190 -
CV004-007 Thrombosis Chamber Study
|
Phase 1 | |
| Completed |
NCT02341638 -
Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BMS-986141 in Healthy Subjects
|
Phase 1 | |
| Completed |
NCT01855516 -
Partial Thromboplastin Time After 72 Hours of Antithrombotic Prophylaxis Using Unfractionated Heparin
|
N/A | |
| Unknown status |
NCT00983112 -
Evicel Study on the Peri-operative Bleeding in Total Knee Prothesis Surgery
|
Phase 4 | |
| Completed |
NCT00412464 -
Pilot Dose Finding and Pharmacokinetic Study of Fondaparinux in Children With Thrombosis
|
Phase 1 | |
| Completed |
NCT00346424 -
Safety and Efficacy Study of Alfimeprase in Subjects With Occluded Central Catheters
|
Phase 3 | |
| Completed |
NCT00479362 -
Anticoagulant Therapy During Pacemaker Implantation
|
Phase 4 | |
| Terminated |
NCT00303420 -
Alteplase for Blood Flow Restoration in Hemodialysis Catheters
|
Phase 4 | |
| Completed |
NCT00143715 -
Oral Vitamin K for Warfarin Associated Coagulopathy
|
Phase 3 | |
| Completed |
NCT00039858 -
Evaluation of Argatroban Injection in Pediatric Patients Requiring Anticoagulant Alternatives to Heparin
|
Phase 4 | |
| Completed |
NCT00007410 -
Genetic Architecture of Plasma T-PA and PAI-1
|
N/A | |
| Completed |
NCT00000538 -
Dietary Effects on Lipoproteins and Thrombogenic Activity
|
Phase 3 | |
| Completed |
NCT00005436 -
Lupus Cohort--Thrombotic Events and Coronary Artery Disease
|
N/A |